A biological definition of neuronal α-synuclein disease : towards an integrated staging system for research
Copyright © 2024 Elsevier Ltd. All rights reserved..
Parkinson's disease and dementia with Lewy bodies are currently defined by their clinical features, with α-synuclein pathology as the gold standard to establish the definitive diagnosis. We propose that, given biomarker advances enabling accurate detection of pathological α-synuclein (ie, misfolded and aggregated) in CSF using the seed amplification assay, it is time to redefine Parkinson's disease and dementia with Lewy bodies as neuronal α-synuclein disease rather than as clinical syndromes. This major shift from a clinical to a biological definition of Parkinson's disease and dementia with Lewy bodies takes advantage of the availability of tools to assess the gold standard for diagnosis of neuronal α-synuclein (n-αsyn) in human beings during life. Neuronal α-synuclein disease is defined by the presence of pathological n-αsyn species detected in vivo (S; the first biological anchor) regardless of the presence of any specific clinical syndrome. On the basis of this definition, we propose that individuals with pathological n-αsyn aggregates are at risk for dopaminergic neuronal dysfunction (D; the second biological anchor). Our biological definition establishes a staging system, the neuronal α-synuclein disease integrated staging system (NSD-ISS), rooted in the biological anchors (S and D) and the degree of functional impairment caused by clinical signs or symptoms. Stages 0-1 occur without signs or symptoms and are defined by the presence of pathogenic variants in the SNCA gene (stage 0), S alone (stage 1A), or S and D (stage 1B). The presence of clinical manifestations marks the transition to stage 2 and beyond. Stage 2 is characterised by subtle signs or symptoms but without functional impairment. Stages 2B-6 require both S and D and stage-specific increases in functional impairment. A biological definition of neuronal α-synuclein disease and an NSD-ISS research framework are essential to enable interventional trials at early disease stages. The NSD-ISS will evolve to include the incorporation of data-driven definitions of stage-specific functional anchors and additional biomarkers as they emerge and are validated. Presently, the NSD-ISS is intended for research use only; its application in the clinical setting is premature and inappropriate.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
The Lancet. Neurology - 23(2024), 2 vom: 22. Jan., Seite 178-190 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Simuni, Tanya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 26.01.2024 Date Revised 26.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/S1474-4422(23)00405-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367576139 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367576139 | ||
| 003 | DE-627 | ||
| 005 | 20240126232200.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240125s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1474-4422(23)00405-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1271.xml |
| 035 | |a (DE-627)NLM367576139 | ||
| 035 | |a (NLM)38267190 | ||
| 035 | |a (PII)S1474-4422(23)00405-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Simuni, Tanya |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A biological definition of neuronal α-synuclein disease |b towards an integrated staging system for research |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.01.2024 | ||
| 500 | |a Date Revised 26.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Parkinson's disease and dementia with Lewy bodies are currently defined by their clinical features, with α-synuclein pathology as the gold standard to establish the definitive diagnosis. We propose that, given biomarker advances enabling accurate detection of pathological α-synuclein (ie, misfolded and aggregated) in CSF using the seed amplification assay, it is time to redefine Parkinson's disease and dementia with Lewy bodies as neuronal α-synuclein disease rather than as clinical syndromes. This major shift from a clinical to a biological definition of Parkinson's disease and dementia with Lewy bodies takes advantage of the availability of tools to assess the gold standard for diagnosis of neuronal α-synuclein (n-αsyn) in human beings during life. Neuronal α-synuclein disease is defined by the presence of pathological n-αsyn species detected in vivo (S; the first biological anchor) regardless of the presence of any specific clinical syndrome. On the basis of this definition, we propose that individuals with pathological n-αsyn aggregates are at risk for dopaminergic neuronal dysfunction (D; the second biological anchor). Our biological definition establishes a staging system, the neuronal α-synuclein disease integrated staging system (NSD-ISS), rooted in the biological anchors (S and D) and the degree of functional impairment caused by clinical signs or symptoms. Stages 0-1 occur without signs or symptoms and are defined by the presence of pathogenic variants in the SNCA gene (stage 0), S alone (stage 1A), or S and D (stage 1B). The presence of clinical manifestations marks the transition to stage 2 and beyond. Stage 2 is characterised by subtle signs or symptoms but without functional impairment. Stages 2B-6 require both S and D and stage-specific increases in functional impairment. A biological definition of neuronal α-synuclein disease and an NSD-ISS research framework are essential to enable interventional trials at early disease stages. The NSD-ISS will evolve to include the incorporation of data-driven definitions of stage-specific functional anchors and additional biomarkers as they emerge and are validated. Presently, the NSD-ISS is intended for research use only; its application in the clinical setting is premature and inappropriate | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a alpha-Synuclein |2 NLM | |
| 700 | 1 | |a Chahine, Lana M |e verfasserin |4 aut | |
| 700 | 1 | |a Poston, Kathleen |e verfasserin |4 aut | |
| 700 | 1 | |a Brumm, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Buracchio, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Chowdhury, Sohini |e verfasserin |4 aut | |
| 700 | 1 | |a Coffey, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Concha-Marambio, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Dam, Tien |e verfasserin |4 aut | |
| 700 | 1 | |a DiBiaso, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Foroud, Tatiana |e verfasserin |4 aut | |
| 700 | 1 | |a Frasier, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Gochanour, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Jennings, Danna |e verfasserin |4 aut | |
| 700 | 1 | |a Kieburtz, Karl |e verfasserin |4 aut | |
| 700 | 1 | |a Kopil, Catherine M |e verfasserin |4 aut | |
| 700 | 1 | |a Merchant, Kalpana |e verfasserin |4 aut | |
| 700 | 1 | |a Mollenhauer, Brit |e verfasserin |4 aut | |
| 700 | 1 | |a Montine, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Nudelman, Kelly |e verfasserin |4 aut | |
| 700 | 1 | |a Pagano, Gennaro |e verfasserin |4 aut | |
| 700 | 1 | |a Seibyl, John |e verfasserin |4 aut | |
| 700 | 1 | |a Sherer, Todd |e verfasserin |4 aut | |
| 700 | 1 | |a Singleton, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Stephenson, Diane |e verfasserin |4 aut | |
| 700 | 1 | |a Stern, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Soto, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Tanner, Caroline M |e verfasserin |4 aut | |
| 700 | 1 | |a Tolosa, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Weintraub, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Yuge |e verfasserin |4 aut | |
| 700 | 1 | |a Siderowf, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Dunn, Billy |e verfasserin |4 aut | |
| 700 | 1 | |a Marek, Kenneth |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Neurology |d 2002 |g 23(2024), 2 vom: 22. Jan., Seite 178-190 |w (DE-627)NLM126098468 |x 1474-4465 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2024 |g number:2 |g day:22 |g month:01 |g pages:178-190 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1474-4422(23)00405-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2024 |e 2 |b 22 |c 01 |h 178-190 | ||